20.500.12556/RUL-144197 Electrochemotherapy as an alternative treatment option to pelvic exenteration for recurrent vulvar cancer of the perineum region Objective: Pelvic exenteration in women with recurrent vulvar carcinoma is associated with high morbidity and mortality and substantial treatment costs. Because pelvic exenteration severely affects the quality of life and can lead to significant complications, other treatment modalities, such as electrochemotherapy, have been proposed. The aim of this study was to evaluate the feasibility and suitability of electrochemotherapy in the treatment of recurrent vulvar cancer. We aimed to analyze the treatment options, treatment outcomes, and complications in patients with recurrent vulvar cancer of the perineum. Methods: A retrospective analysis of patients who had undergone pelvic exenteration for vulvar cancer at the Institute of Oncology Ljubljana over a 16-year period was performed. As an experimental, less mutilating treatment, electrochemotherapy was performed on one patient with recurrent vulvar cancer involving the perineum. Comparative data analysis was performed between the group with pelvic exenteration and the patient with electrochemotherapy, comparing hospital stay, disease recurrence after treatment, survival after treatment in months, and quality of life after treatment. Results: We observed recurrence of disease in 2 patients with initial FIGO stage IIIC disease 3 months and 32 months after pelvic exenteration, and they died of the disease 15 and 38 months after pelvic exenteration. Two patients with FIGO stage IB were alive at 74 and 88 months after pelvic exenteration. One patient with initial FIGO stage IIIC was alive 12 months after treatment with electrochemotherapy with no visible signs of disease progression in the vulvar region, and the lesions had a complete response. The patient treated with electrochemotherapy was hospitalized for 4 days compared with the patients with pelvic exenteration, in whom the average hospital stay was 19.75 (± 1.68) days. Conclusion: Our experience has shown that electrochemotherapy might be a less radical alternative to pelvic exenteration, especially for patients with initially higher FIGO stages. vulvar cancer electrochemotherapy surgery pelvic exenteration recurrent disease rak vulve elektrokemoterapija kirurgija true false true Angleški jezik Slovenski jezik Članek v reviji 2023-02-03 13:31:37 2023-02-03 13:31:43 2023-02-04 03:48:10 0000-00-00 00:00:00 2022 0 0 7 str. Vol. 21 2022 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 618.1 1533-0338 10.1177/15330338221116489 117591811 15330338221116489.pdf 15330338221116489.pdf 1 86B2372AC4A98D74EADBFDC19F78867D 469fb72af67ca86c6b2e68215314da004bf7f5630e42f7adc95f2e46f79d529d a91f1d58-a3be-11ed-9c94-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=166398 https://journals.sagepub.com/doi/10.1177/15330338221116489 0 7cfec6ca-a3be-11ed-9c94-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=166397 Medicinska fakulteta Zdravstvena fakulteta Fakulteta za farmacijo 0 0 0